Internal Medicine, Cardiovascular Disease · Great Neck, NY
NPI
1508869884
Since 2005
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
287 Northern Blvd, Ste 211
Great Neck, NY, 11021
Phone (516) 482-3401
Groups this clinician bills Medicare through
Medicare paid, 2024
$502K
19,283 services
Medicare patients, 2024
1,048
Average age 75
Drug cost, 2024
$884K
7,043 prescriptions
Company payments, 2025
$2,287
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Guy L Mintz was code J1306 (injection, inclisiran, 1 mg), 13,916 times for 32 patients. In total Guy L Mintz billed 19,283 services in 26 codes, and Medicare paid $502K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 13,916 | 32 | $9.53 | $133K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,460 | 827 | $14.33 | $21K |
| 99214 Office E&M - Established | Office | 1,291 | 746 | $105.08 | $136K |
| 93000 Electrocardiogram | Office | 941 | 691 | $12.02 | $11K |
| 93306 Echocardiography (TTE/TEE) | Office | 602 | 597 | $173.30 | $104K |
| 99213 Office E&M - Established | Office | 217 | 211 | $74.23 | $16K |
| 93015 Electrocardiogram | Office | 207 | 206 | $56.40 | $12K |
| 99215 Office E&M - Established | Office | 189 | 152 | $159.56 | $30K |
| 93880 Duplex Scan - Extracranial Arteries | Office | 101 | 101 | $180.50 | $18K |
| 99204 Office E&M - New | Office | 73 | 73 | $129.44 | $9,449 |
| 99203 Office E&M - New | Office | 49 | 49 | $79.58 | $3,900 |
| 96372 Injection Administration | Office | 48 | 31 | $13.35 | $641 |
| 93784 External Electrocardiographic Monitoring | Office | 44 | 44 | $38.86 | $1,710 |
| 93248 Electrocardiogram | Office | 42 | 34 | $21.89 | $919 |
| 93246 Electrocardiogram | Office | 38 | 35 | $10.12 | $384 |
By year: 2022 $394K for 5,880 services; 2023 $388K for 7,787 services; 2024 $502K for 19,283 services.
Medicare prescription drug claims, 2024
In 2024, the drug Guy L Mintz prescribed most often to Medicare patients was Rosuvastatin Calcium, with 1,265 prescriptions and refills. In total Guy L Mintz wrote 7,043 Medicare prescriptions that cost $884K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 1,265 | 3,536 | 430 | $20K |
| Ezetimibe Generic | 744 | 2,100 | 269 | $23K |
| Telmisartan Generic | 719 | 1,961 | 244 | $21K |
| Atorvastatin Calcium Generic | 548 | 1,538 | 182 | $6,752 |
| Metoprolol Succinate Generic | 526 | 1,478 | 182 | $8,826 |
| Amlodipine Besylate Generic | 447 | 1,264 | 161 | $2,671 |
| Telmisartan-Hydrochlorothiazid Telmisartan/Hydrochlorothiazid | 276 | 789 | 95 | $27K |
| Potassium Chloride Generic | 234 | 648 | 84 | $4,245 |
| Repatha Sureclick Evolocumab | 172 | 348 | 44 | $192K |
| Hydrochlorothiazide Generic | 172 | 484 | 57 | $790 |
| Xarelto Rivaroxaban | 167 | 406 | 57 | $218K |
| Labetalol Hcl Generic | 137 | 373 | 54 | $5,358 |
| Eliquis Apixaban | 107 | 223 | 34 | $125K |
| Metoprolol Tartrate Generic | 105 | 287 | 42 | $550 |
| Pravastatin Sodium Generic | 91 | 260 | 38 | $1,355 |
Brand drugs: 678 claims; generic drugs: 6,365 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Guy L Mintz $2,287 ($2,287 in general payments such as food, travel and fees) from 7 companies. The largest payer was Kaneka Medical America LLC with $1,750.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.